# A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

> clinical trial · VERIFIED · 2026-06-26

Status: RECRUITING · Sponsor: Bristol-Myers Squibb · Condition: Metastatic Non-small Cell Lung Cancer With MTAP Deletion

- Company: Bristol-Myers Squibb
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07063745

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.